Reneuron gets US patent for non-toxic cell cryopreservation system

By Gareth Macdonald contact

- Last updated on GMT

Reneuron gets US patent for cryopreservation tech
Reneuron gets US patent for cryopreservation tech

Related tags: Stem cell

Reneuron has been granted a US patent for a cryopreservation technology that does not rely on toxic reagents and says it would consider licensing it to other stem cell therapy developers on a case-by-case basis.

The patent – no. 13/132,475 – covers technology that can freeze and thereby extend the shelf life of the neural, retinal and mesenchymal cells according to Reneuron.

A spokesman told us the technology is used to “freeze the cells in order that they can be readily shipped and stored with a long shelf life​” adding that  “they are then thawed at the site and administered when required​.”

Reneuron said the tech in question is a “formulation” but did not go into additional details.

The spokesman did say that: “We have developed our own formulation which is optimal for our cells and avoids the need for toxic cryopreservants typically found in marketed solutions​.”

Clinical trial

Reneuron has used the technology to develop an extended shelf life version of its ischemic stroke therapy – CTX stem cell. The developmental therapy is made at Reneuron's facility in Pencoed, Wales and distributed to clinical trial sites across the UK.

Last August​, the firm installed new processing technology to automate production of CTX ahead of late phase trials. The cryopreservation technology covered by the new US patent is a further effort to streamline the manufacturing process.

However, the US patent does open up other possibilities for Reneruon beyond protecting its own cell therapy products.

The firm’s spokesman told us “The primary purpose of the patent is to protect our technology assets.  Should a third party wish to utilise the technology, we would consider granting licenses on a case-by-case basis​.”

Related topics: Downstream Processing, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more